Key Highlights

  • CDT shares trading down 14.16% today to $0.0661, versus an implied prior close of about $0.077.
  • A data page showed a market Capitalization near $205,000 and about 1.12 million shares outstanding as of Oct. 19.
  • The board approved a 1-for-25 Reverse Stock Split on Sept. 25.
  • CDT issued a $6.75 million senior secured convertible note on Oct. 13, after a $2.13 million note in September.
  • Trailing net loss was about $37.15 million, with four employees reported.

No Company Trigger Found for CDT Equity's Latest Slide to $0.0661

CDT Equity (NASDAQ:CDT) shares are trading down 14.16% today at $0.0661, and no company-specific announcement explaining the move was identified. Recent headlines include an Oct. 27 evaluation deal with Manoira and an Oct. 30 headline about the company welcoming interim U.S. policy supporting compounded peptide access. Neither was found to address today's decline, and the stock has now fallen sharply across several sessions this month.

CDT Equity describes itself as a data-driven biopharmaceutical company that identifies, enhances and monetizes therapeutic assets. Its pipeline includes AZD1656, in Phase II for autoimmune disorders, AZD5658, in Phase I for Type 2 diabetes, and AZD5904, which has completed Phase I for idiopathic male infertility. The company also holds a 22.7% stake in Sarborg.

Convertible Notes and a 1-for-25 Reverse Split Define the Funding Backdrop

The board approved a 1-for-25 reverse stock split on Sept. 25, with the company saying the step was aimed at maintaining Nasdaq bid-price compliance. A Trading halt with news pending was also reported on Sept. 29. A data page showed a 52-week range running from $0.1813 up to $28,125, a spread that likely reflects reverse split adjustments, though the page does not say so.

CDT issued a $2.13 million senior secured convertible note to J.J. Astor & Co in September, followed by a $6.75 million note to the same investor on Oct. 13. A filing headline tied one note, maturing March 24, 2027, to 24 weekly installments of $168,750. As of Oct. 19, the stock had fallen 22.37% to $0.1825 that day, with roughly 1.12 million shares outstanding.

Manoira, QIMA and Pep'd Partnerships Broaden the Asset Story

On Oct. 27, CDT Equity said it will give Manoira access to materials from AZD1656, including certain cocrystal derivatives, and from AZD5904 to evaluate animal health products. On Sept. 18, it announced a Partnership with QIMA Life Sciences to test tapinarof combinations in psoriasis and vitiligo. In August, it disclosed a SAFE note Investment in Pep'd, a U.S. peptide company.

Co-founder James Bligh was appointed CEO on Sept. 1. Earlier, on Aug. 3, the company announced a transaction to raise its stake in Sarborg, which it has highlighted for Patent filings and Quantum Computing work in drug discovery.

Thin Market Value, Heavy Losses and Note Repayments Keep Financing in Focus

Trailing net loss was about $37.15 million, while the market capitalization shown on the data page was only about $205,000. The company reported stockholders' equity of roughly $103 million in its quarterly filing for the period ended June 30, a figure that sits far from the Market Value and could not be reconciled with the share price. Weekly note installments, any further reverse split effects and the next quarterly filing are the items to follow, as are updates on the Manoira and QIMA collaborations and any further capital raises.